Quick Takeaways
- PharmaCyte Biotech, Inc. filed SCHEDULE 13G for FEMASYS INC Common Stock, par value $0.0001 per share (FEMY).
- Disclosed ownership: 7.9%.
- Date of event: 17 Mar 2026.
PharmaCyte Biotech, Inc. - 17 Mar 2026 SCHEDULE 13G Report for FEMASYS INC Common Stock, par value $0.0001 per share (FEMY)
- Filing Manager
- PharmaCyte Biotech, Inc.
- Reporting Manager
- PharmaCyte Biotech, Inc.
- Symbol
- FEMY
- Shares outstanding
- 62,678,844 shares
- Disclosed Ownership
- 4,932,825 shares
- Ownership
- 7.9%
- Form type
- SCHEDULE 13G
- Filing time
- 18 Mar 2026, 17:00:01 UTC
- Date of event
- 17 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"PharmaCyte Biotech, Inc. disclosed 7.9% ownership in FEMASYS INC Common Stock, par value $0.0001 per share (FEMY) on 17 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 18 Mar 2026, 17:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. | 7.9% | 4,932,825 | 4,932,825 | 0 | /s/ Joshua N. Silverman | Joshua N. Silverman, Chief Executive Officer and President |